Last updated on: May 29, 2026

Annual Report on Forced and Child Labour in Supply Chains

This Report is published pursuant to the Canadian “Fighting Against Forced Labour and Child Labour in Supply Chains Act” and sets out the steps that Medisca Pharmaceutique Inc. (“Medisca”) has taken and is continuing to take to combat forced and child labour in our business and supply chains. The report covers activities undertaken during the entity’s previous financial year, from June 1, 2025 through May 31, 2026 (the “2025 Reporting Year”).

Introduction

Medisca is committed to complying with the requirements of Canada's Fighting Against Forced Labour and Child Labour in Supply Chains Act, and to reporting on its efforts to identify and manage potential risks of forced and child labour.  We strive to ensure that forced or child labour is not present in our business or supply chains and take our responsibility to address related risks appropriately. We are committed to acting ethically, with integrity and being transparent. Responsible sourcing is integral to Medisca’s commitment to product quality, patient safety, regulatory compliance, and long-term supply chain resilience. Labour rights considerations are embedded within our strategic business framework that prioritizes operational excellence and risk governance.

Medisca continues to review and enhance its policies and procedures to further integrate forced and child labour considerations and reflect evolving regulatory expectations and best practices.

Our business and supply chain

Founded in 1989, Medisca is a global leader in personalized medicine and pharmaceutical supply chain solutions, with a vast portfolio of over 2,000 products completed by a library of 10,000+ proprietary and customized medication formulas, expertise and services in pharmaceutical compounding, continuing healthcare education, analytical testing, and more. Providing finely-tuned solutions to diverse wellness sectors across the globe, Medisca is bridging the gaps in healthcare and empowering personalized wellness for all.

Medisca sources its products from a global network of suppliers and manufacturers originating in various countries, including China, India, South Korea, Malaysia, Europe, Australia, and North America. These products are delivered to Medisca’s facilities located in Canada (Montreal, Quebec and Richmond, British Columbia), the U.S. (Plattsburgh, New York and Irving, Texas) as well as Australia (Mascot, New South Wales) via various logistics providers, carriers and shipping companies.

All suppliers, manufacturers, logistic providers, carriers and shipping companies are subject to a vendor qualification program to verify or maintain the quality and integrity of the products. Certain products are also subjected to third party analytical testing laboratories located in Canada, the U.S., and Australia. Our sourcing spans regulated pharmaceutical inputs, specialized equipment and materials, and a smaller set of non-regulated pharmaceutical items and ancillary supplies, each managed through appropriate internal controls. This diversified sourcing model allows Medisca to manage a broad range of inputs while maintaining consistent qualification, monitoring, and risk based reassessment across all suppliers.

Our primary customers are compounding pharmacies, wholesalers and hospitals. All products ordered by customers in Canada are delivered by Medisca directly from our facilities located in Canada, and on occasion directly from Medisca’s affiliated company and facilities located in the United States. In certain instances, products may be drop-shipped directly from the supplier or manufacturer to the customer. Maintenance services for certain electromechanical products are also available to our customers through service centers located in Canada, the United States and Australia. Sales of our products are performed through various affiliates and offices of Medisca and remote workers located in Canada, the United States and Australia. This integrated distribution and service network supports Medisca’s global operations and reflects the scale and diversity of its supply chain.

Governance

As a participant in a highly regulated pharmaceutical sector, Medisca operates under strict global standards that require robust oversight of our supply chain. Medisca’s governance of supply chain oversight is further supported through regular management reviews and executive collaboration. This structure provides the Board visibility and senior leadership engagement in supply chain practices, reinforcing our commitment to responsible and compliant operations.

Policies and Due diligence processes

Over the course of the 2025 Reporting Year, the organization has conducted a comprehensive strategic review of its policies. Following this review, a decision was made to establish a distinct Supplier Code of Conduct specifically addressing the mitigation of forced labor and child labor risks. This approach was chosen in lieu of incorporating such mitigation measures into the organization’s existing Culture Code, Workplace Harassment Policy, and Health and Safety Policy. Notwithstanding the creation of the Supplier Code of Conduct, the aforementioned policies remain fundamental components of the organization’s overarching framework supporting ethical business practices and supply chain integrity. Relevant policies are outlined below.

The Culture Code sets forth the fundamental policies governing ethical conduct within the organization. It establishes standards and guidelines for the behavior of Medisca employees in their interactions with colleagues, customers, and third parties.

The Workplace Non-Harassment Policy is designed to foster a work environment free from all forms of harassment, offensive behavior, discrimination, and workplace violence. This policy strictly prohibits all types of harassment and provides clear definitions encompassing various forms, including psychological harassment, sexual harassment, vexatious conduct, and workplace violence. The organization is committed to maintaining a culture of integrity and ensuring that employees have access to confidential and secure channels for reporting concerns, with assurances of protection against retaliation.

Lastly, over the 2025 Reporting Year, Medisca’s primary objective has been to draft a Supplier Code of Conduct as an appendix to its existing supplier terms. This Code establishes Medisca’s expectations with respect to the prohibition of forced and child labour, and sets out requirements relating to due diligence, reporting, and grievance mechanisms at the supplier level. The Code will be implemented on a phased basis, beginning with domestic suppliers, to establish clear expectations and a consistent baseline for engagement. Moving forward, Medisca will begin operationalizing the Supplier Code of Conduct with suppliers who are due for new or renewed agreements. Supplier acknowledgement and signature will serve as the first level of compliance confirmation. For suppliers who do not acknowledge immediately, we will work with them to achieve compliance.

We have robust supplier assessment and due diligence processes that serve as a foundation. While these processes do not currently address forced and child labour risks, they offer a base we can build on to enhance visibility into these risks going forward. These processes will be progressively strengthened to support the next phase of our due diligence enhancements. As Medisca’s sourcing portfolio includes both regulated pharmaceutical inputs and non-regulated items such as ancillary supplies, our due diligence approach is calibrated to reflect the regulatory requirements and risk profile of each product category.

At Medisca, we have an unwavering commitment to quality, which is reflected in our meticulous sourcing, manufacturer qualification, and comprehensive product testing. To ensure the highest standards, we have established quality agreements  with our active pharmaceutical ingredient (API) and certain device manufacturers, as well as with contract manufacturers who produce ready bases for our industry. All API and medical device manufacturers are governed by regulatory bodies, their licensed activities for compliance with good manufacturing practices and related quality standards.

In addition to our quality agreements, additional documentation is requested, as part of the qualification process, and based on the supplier and product type risk profile. These may include, but are not limited to, methods, testing protocols, Supplier Assessment Forms, Product Assessment Forms, inspection reports, certificates of GMP compliance, and related evidence. Qualification activities may also involve verification of site establishment licences and certifications, as well as any product specific licensing, accreditation, or authorization requirements applicable to both regulated and non regulated goods. This risk based approach ensures that regulated suppliers are subject to GMP aligned oversight, while non-regulated suppliers are evaluated through controls appropriate to their category and risk level.

Our supplier assessment form is a comprehensive assessment that evaluates key aspects of our suppliers' operations. The various forms cover essential information such as site compliance history with regulatory agencies, product specifications and supplier attestation to any changes in their establishment and any change that could reasonably affect the safety, performance or effectiveness of the product(s) purchased by Medisca. This thorough evaluation process helps us ensure that our suppliers meet our high standards for quality and compliance.

Medisca reviews its policies and procedures on a regular basis and will continue to do so to reflect its processes, continuous improvement and compliance with applicable laws and regulations.

Forced and child labour risks

In the 2023 reporting year, we undertook an independent assessment to better understand the risks of forced and child labour associated with the country of origin of our procured products and broader supply chain risk exposure. We began by analyzing goods where Medisca Pharmaceutique Inc. was the importer of record into Canada.

For the 2024 reporting period, our initial supply chain review was anchored in 2023 import data, which provided a foundational snapshot of our foreign Tier 1 suppliers.

Building on this work, the 2025 Reporting Year expanded the scope to include domestic Tier 1 suppliers, allowing us to evaluate risks across our full first tier network. This evolution has enabled us to move beyond a single year import baseline toward a broader, risk based methodology.

Through these processes, no risks related to forced or child labour were identified in the 2025 Reporting Year.

This section will continue to be refined as our methodology matures and as additional data sources become available.

Remediation measures and remediation of loss of income

Medisca acknowledges the importance of vigilance and ongoing monitoring to ensure that forced and child labour risks remain mitigated within our operations and supply chains. To date, we have not identified any incidents of forced labour and child labour in our own operations, nor in our supply chain. No incidents requiring remediation were identified during the 2025 Reporting Year.

Additionally, Medisca has not identified any circumstances requiring measures to remediate loss of income to vulnerable families. We will regularly review our risk assessments and implement any necessary remediation measures should the need arise.

In the event that any forced labour or child labour is found in our business and supply chains, we will immediately implement the appropriate remediation strategies in compliance with applicable standards.

Training

All new employees at Medisca are required to complete onboarding training that encompasses key elements of Medisca’s policies, including but not limited to the Workplace Harassment Policy. These policies collectively establish the standards for expected ethical behavior within the company.

Additionally, the People & Culture team is currently evaluating options to introduce training aimed at increasing employee awareness of the risks associated with forced and child labor. This initiative remains in its preliminary stages, and Medisca continues to evaluate the most effective methodology for its future implementation.

Assessing effectiveness

Medisca has identified certain measures aimed at reducing the risk of forced and child labour in our operations and supply chain. We are in the early stages of developing a formal approach to evaluating the effectiveness of our efforts to prevent forced labour and child labour in our business and supply chains. We will report on relevant progress as these measures are developed and implemented.

In accordance with the requirements of the Fighting Against Forced and Child Labour in Supply Chains Act (Act), and in particular section 11 thereof, I, in the capacity of Founder and Chairman of the Board, attest that I have reviewed the information contained in the report on behalf of the governing body of the entity [or entities] listed above. Based on my knowledge, and having exercised reasonable diligence, I attest that the information in the report is true, accurate and complete in all material respects for the purposes of the Act, for the 2025 Reporting Year.

I have the authority to bind Medisca Pharmaceutique Inc.

Full Name: Antonio Dos Santos

Title: Founder and Chairman of the Board

Date: 29 May 2026

To contact Medisca, please click here.